Chicago, IL (PRWEB) February 17, 2014
Analyte Health (http://www.analytehealth.com), the leader in online diagnostic triage, announced today that over 1 million tests for HIV and other sexually transmitted diseases have been administered to consumers who seek early detection and treatment of infections since its online diagnostic triage service launched in 2009.
"Every day, Analyte Health helps thousands of consumers who are concerned about their sexual health. This milestone is a very encouraging sign for healthcare. People are willing to take control of their own health if they are offered a simple, convenient and consumer-friendly way to do it. We look forward to extending our service for those who seek early detection of diabetes, cardiovascular disease, and other serious health threats,” said Sridhar Murthy, CEO of Analyte Health.
While there are 20 million new cases of STDs every year, millions more go undiagnosed and unreported. As a result, the annual surveillance report by the Centers for Disease Control (CDC) captures only a fraction of the true burden of STDs in America. STDs are a significant drain on the U.S. health care system, costing almost $16 billion in health care costs every year for the treatment of serious complications.
Analyte Health surveys its patients, asking about their STD testing history, and 43% report that they have never previously had an STD test despite clinical guidelines recommending screening for individuals who have higher risk behavior. Of the over 160,000 people Analyte Health has tested and triaged, 80% are men who do not routinely seek preventive healthcare.
“There are many reasons people, specifically men, choose not to get preventive health care,” said Dr. Ramesh Subramani, Chief Medical Officer. “We understand the problems inherent in the traditional system and have designed our digital diagnostic service to address those barriers that prevent so many from getting the care they need. When we look at how many people have been diagnosed and treated for STDs who have never been tested before, we are proud of the impact we are having for the health and well-being of sexually active adults.”
Analyte Health also tests for other serious illnesses that are transmitted via blood, including Hepatitis B and Hepatitis C, which pose a significant health risk to individuals, and a substantial and growing cost to the system.
To date, Analyte Health has helped over 160,000 people learn their STD status and, when diagnosed for an STD, has triaged them into care:
“We are proud of this milestone,” said Sridhar Murthy. “We believe that STD testing is a critical beginning as we continue to break down other barriers to the prevention and treatment of diseases that go undetected, undiagnosed, unreported and untreated in this country.”
About Analyte Health, Inc.
Analyte Health is a diagnostic triage company. Its mission is to provide convenient access to education, diagnostic testing, personalized results and recommendations to consumers through its Online Clinics. Analyte Health offers access to healthcare via the phone and the web to a national team of doctors and partner diagnostic labs. Over 160,000 patients have trusted Analyte Health to deliver convenient and private STD testing and care. More information about the company is available at http://www.AnalyteHealth.com.
Analyte Health, Inc. is a privately held company. This press release may be deemed to contain forward-looking statements, which are subject to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including statements regarding the expected benefits to consumers from using Analyte Health's services. Readers are cautioned that these forward-looking statements are only predictions and may differ materially from actual future events or results due to a variety of risks and uncertainties, including, among other things, the potential impact of regulatory and third party payer developments in the field of telehealth and STD testing, general business and economic conditions, changes in arrangements with vendors or suppliers, and costs or delays in obtaining or maintaining regulatory approvals and licenses. Any forward-looking statements in this release are based on limited information currently available to Analyte Health, which is subject to change, and Analyte Health will not necessarily update the information.